Introduction
Obesity has reached pandemic proportions affecting millions of individuals in developing as well as developed countries [1, 2] . Obesity is associated with lowgrade systemic inflammation, which is considered a major mechanism driving insulin resistance in obese individuals [3] [4] [5] . Insulin resistance describes a condition in which elevated levels of plasma insulin are required to maintain normal fasting or postprandial glucose levels [5] . Insulin resistance is considered a key initiating factor in the deleterious effects of obesity on health, including glucose intolerance, dyslipidemia and increased risk of nonalcoholic fatty liver disease (NAFLD), type 2 diabetes, atherosclerosis, hypertension, ischemic heart disease and cancer [6 ,7] . Defining the sources, causes and mechanisms underlying the development of inflammation and insulin resistance during progressive increases in body weight and adiposity is therefore central to the development of strategies and therapies to prevent or limit the adverse effects of obesity on health. To date, a majority of studies have focused on adipose tissue, particularly visceral adipose tissue, as the source of inflammation and proinflammatory cytokines in obese humans or animal models as described in a recent comprehensive review [7] . This review will summarize recent evidence that diet-induced inflammation in the intestine, particularly the small intestine, may represent an early event that precedes and predisposes to obesity and insulin resistance. Evidence that intestinal microbiota interact with diet to mediate intestinal inflammation and the mechanisms by which these interactions may promote obesity or insulin resistance is also reviewed.
Purpose of review
To highlight recent evidence supporting a concept that intestinal inflammation is a mediator or contributor to development of obesity and insulin resistance. Recent findings Current views suggest that obesity-associated systemic and adipose tissue inflammation promote insulin resistance, which underlies many obesity-linked health risks. Diet-induced changes in gut microbiota also contribute to obesity. Recent findings support a concept that high-fat diet and bacteria interact to promote early inflammatory changes in the small intestine that contribute to development of or susceptibility to obesity and insulin resistance. This review summarizes the evidence supporting a role of intestinal inflammation in diet-induced obesity and insulin resistance and discusses mechanisms.
Summary
The role of diet-induced intestinal inflammation as an early biomarker and mediator of obesity, and insulin resistance warrants further study. phosphorylation of IRS-1 and IRS-2, which limit the ability of IRS proteins to activate downstream pathways [5] . Although adipocytes are unquestionable sources of inflammation in obesity, increasing evidence suggests that obesogenic diets may stimulate inflammation in other organs [9 ,10].
Keywords

Intestinal inflammation in diet-induced obesity
Until recently, the potential role of intestinal inflammation as a mediator or contributor to obesity has received relatively little attention. This is because chronic inflammatory bowel diseases (IBD), such as Crohn's disease or ulcerative colitis, are associated with damage to the intestinal epithelium, malabsorption and weight loss. However, it is important to emphasize that the systemic and local tissue inflammation associated with diet-induced obesity is less severe than in chronic IBD.
High-fat diet and intestinal inflammation in animal models
The gastrointestinal tract is the first organ to be exposed to dietary components, like diets high in saturated fat, that promote obesity. In a recent study, C57BL6 mice were exposed to high-fat or low-fat diets (HFD and LFD) and expression of multiple proinflammatory cytokines was assessed in small intestine and colon. Of many cytokines assayed, only TNFa was upregulated by HFD, and this occurred specifically in the ileum and within 2-6 weeks of HFD, preceding diet-induced weight gain and increased fat mass [9 ] . Importantly, the increases in ileal TNFa mRNA showed strong and significant correlations with the degree of weight gain, increases in fat mass, and increases in plasma glucose or insulin [9 ] . In this study, there were no detectable increases in plasma TNFa or other cytokines, suggesting that local upregulation of ileal TNFa was a more sensitive measure of dietinduced inflammation than circulating cytokine levels at least in this animal model [9 ] . An NF-kBRE EGFPreporter mouse expressing a transgene composed of NF-kB response elements driving enhanced green fluorescent protein was used as an independent model to assess intestinal inflammation. Use of this model detected activation of NF-kB-driven transcription in ileum and to a lesser extent colon of mice fed HFD [9 ]. Intriguingly, NF-kB activation was localized to multiple cell types, including intestinal epithelial cells, CD3þ or CD45þ immune cells, endocrine cells and endothelial cells, but not resident F4/80-positive intestinal macrophages [9 ]. This study strongly suggests that intestinal inflammation and proinflammatory signaling in multiple cell types is an early response to HFD and correlates with subsequent development of obesity and insulin resistance. Two other recent studies have demonstrated that HFD induces intestinal inflammation. de La Serre et al. 
Key points
Emerging evidence in animal models suggests that high-fat diet and microbes interact to promote lowgrade inflammation in the small intestine and to a lesser extent colon.
Intestinal inflammation precedes and strongly correlates with diet-induced obesity and insulin resistance. Some but not all studies in humans link obesity and insulin resistance to inflammation in the colon. Better noninvasive biomarkers of diet:microbeinduced small intestinal inflammation in humans are needed.
Intestinal inflammation may promote obesity and insulin resistance by multiple mechanisms. Future studies need to address the specific contributions of intestinal inflammation vs. systemic or adipose inflammation to initiation and progression of obesity and insulin resistance. of C57BL6 mice fed HFD and found induction of macrophage migration inhibitory factor (MIF), which has been associated with obesity and insulin resistance as well as enrichment of inflammation and interferon-g-induced gene subsets in ileum of mice fed HFD.
Evidence for and against intestinal inflammation in obese humans
Recent evidence demonstrates intestinal inflammation in obese humans. Spagnuolo et al.
[13 ] examined a small cohort of severely obese children. Using fecal calprotectin and rectal nitric acid as biomarkers of inflammation, they found that approximately 50% of obese and glucosetolerant children had elevated fecal calprotectin, whereas more than 80% of obese and glucose-intolerant children had elevated rectal nitric oxide. This study indicates that intestinal inflammation occurs in obese humans and suggests that relatively noninvasive calprotectin or nitric oxide assays may be used to monitor obesity-associated intestinal inflammation. The study was, however, limited to a small sample size and severely obese children. Pendyala and Natarajan [14] examined proinflammatory cytokines and gene expression profiles in colon mucosal biopsies from a small cohort of obese women before and after a very low-calorie diet to induce a loss of 10% body weight. They found that weight loss was associated with significant reductions in mucosal TNFa, IL-1b, and IL-8 and dramatic down-regulation of gene networks linked to proinflammatory signaling [15 ] . Together, these animal and human studies strongly support a concept that intestinal inflammation is linked to obesity and insulin resistance.
Counterbalancing these studies are recent findings of Brignardello [16 ] , who found no evidence of colonic inflammation in obese compared with lean adults based on assays of fecal caprotectin and leptin. However, the obese individuals in this study had signs of systemic inflammation based on elevated plasma C-reactive protein but had fasting glucose levels within the normal range. Thus, systemic inflammation and obesity in the absence of detectable colonic inflammation was not associated with insulin resistance. Tiihonen et al. [17 ] also found no increase in fecal calprotectin, TNFa or IgA in obese vs. lean individuals despite systemic inflammation and elevated plasma insulin. However, the lack of inflammation detected in these latter human studies may indicate that the fecal biomarkers do not have optimal sensitivity for detecting intestinal inflammation. Furthermore, in animal models, HFD-induced inflammation is particularly evident in small intestine compared with colon. Additional studies that specifically evaluate small bowel inflammation are therefore required to definitively establish the impact of diet or obesity on intestinal inflammation in humans.
Role of intestinal microbiota in obesityassociated intestinal inflammation
Compelling evidence supports a role of gut microbiota in diet-induced obesity (reviewed in Musso 2011) [18 ] . Although mechanisms are still to be defined, findings that germ-free mice do not develop obesity or insulin resistance when placed on a HFD [19] provide definitive evidence that gut microbiota must be present for deposition of excess dietary energy intake into adipose tissue. Furthermore, colonization of germ-free mice with microbiota from obese vs. lean animals resulted in increased total fat mass, demonstrating a causal role of microbiota in diet-induced obesity [20] . Recent findings demonstrate that microbiota are also necessary for development of intestinal inflammation associated with HFD and obesity. This evidence is based on our findings that germ-free mice fed HFD, as well as being resistant to obesity, do not exhibit upregulation of ileal or colonic TNFa [9 ] . Thus, interactions between HFD and microbiota are required for HFD to induce intestinal inflammation. de La Serre et al.
[11 ] also found that HFD results in activation of ileal toll-like receptor 4 (TLR4) only in obesity-prone but not obesity-resistant rats. Because TLR4 is a primary receptor mediating the proinflammatory effects of lipopolysaccharide (LPS) derived from gram-negative bacteria, this provides important evidence to link bacteria-induced proinflammatory signaling in the intestine to the development of diet-induced obesity. Intriguingly, HFD was associated with reduced levels of small intestinal alkaline phosphatase (IAP), an enzyme that detoxifies LPS [11 ] . Recent findings in IAP-knockout mice suggest that this enzyme is essential to preserve normal gut microbial homeostasis and to protect against pathogenic bacteria [21] . Thus, HFD-induced decreases in IAP may be important determinants of diet:microbe interactions that promote intestinal inflammation.
Although much emphasis is currently placed on dysbiosis or altered microbial communities in obesity, it is important to distinguish general diet-induced changes in microbial communities from those specifically linked to obesity. For example, HFD-altered gut microbial populations in both obesity-prone and obesity-resistant rats [11 ] . Similarly, another report found that HFD led to comparable changes in microbiota in wild-type mice that develop obesity and in RELMb-knockout mice that are resistant to diet-induced obesity [22] . These findings demonstrate the need for caution in interpreting dietinduced changes in microbial communities as causative factors in obesity. Dramatic increases in Enterobacteriales, a member of the minor proteobacteria phylum, have been associated specifically with development of intestinal inflammation and obesity in DIO-P rats fed HFD and were not increased in DIO-R rats [11 ] . This is interesting because enterobacteriaceae have recently been linked to induction of spontaneous colitis in mouse models [23] . Thus, the specific roles of these particular bacteria in intestinal inflammation associated with obesity warrants further study.
Lipopolysaccharide as a key mediator of obesity or inflammation-associated insulin resistance
A body of work by Cani et al. [24] in mouse models demonstrates key roles of increases in systemic LPS, a condition termed 'metabolic endotoxemia' in the development of obesity-associated insulin resistance [25, 26] .
In a large study in healthy men, fat and energy intake were also found to be strongly correlated with increased plasma LPS concentrations [27] . Another study in healthy humans showed that a high-fat/high-carbohydrate meal induced a significant postprandial endotoxemia, coupled with increased expression of TLR4, SOCS3, and NF-kB in circulating mononuclear immune cells [28] . In contrast, there were no increases in these proinflammatory mediators after meals rich in fiber and fruits [28] . Deopurkar et al. [29] compared the effects of isocaloric meals rich in glucose, saturated fat, and orange juice on plasma LPS and inflammatory markers and found that only saturated fat intake was linked to plasma LPS and systemic inflammation markers, including NF-kB, SOCS3, TNFa, and IL-1b expression.
Current evidence suggests that diet-induced changes in intestinal permeability underlie the elevated circulating LPS in obesity. HFD has been shown to reduce intestinal permeability by affecting tight junction proteins, favoring increased translocation of LPS and potentially other proinflammatory markers into the systemic circulation [11 ,26] . Antibiotics, prebiotics, or probiotic bacteria appear to ameliorate this effect and protect against weight gain, systemic inflammation, and insulin resistance [26, 30] . A recent study suggests that LPS may enter the lymph nodes and systemic circulation due to uptake into chylomicrons, which mediate absorption of dietary fat from enterocytes [31] . Thus, current views would support a concept that inflammatory mediators absorbed from the gut due to diet:bacteria interactions promote systemic inflammation and associated insulin resistance.
Other mediators of intestinal inflammation due to diet:bacteria interactions
The complex and extensive interactions between hostdietary factors and microbiota [32] are beyond the scope of this review, and readers are referred to an excellent recent review [18 ] . However, it is important to recognize that many factors other than LPS may promote intestinal inflammation in response to HFD. Diet can alter the profiles of short chain fatty acids (SCFA) produced by bacterial fermentation of indigestible polysaccharides. Ratios of the SCFA butyrate, propionate, and acetate depend on diet pH and microbiota [18 ] . Butyrate has protective effects on intestinal epithelium by multiple mechanisms, including induction of alkaline phosphates and protection against intestinal inflammation [33] . Butyrate also protects against HFD-induced obesity [34] . Thus, alterations in fecal SCFAs due to diet:microbial interactions may favor intestinal inflammation. Other bacterial metabolites such as secondary bile acids, lactate, or phenolics, which have been associated with obesity or insulin resistance [17 ] , and linoleic acid or choline, which have protective effects [18 ] , warrant further examination for roles in diet-associated intestinal inflammation.
Toll-like receptor-5 is protective against colitis and obesity
It is important to recognize that some bacteria-activated signaling pathways may be protective against intestinal inflammation or obesity. TLR5 is a receptor that recognizes bacterial flagellin, and when deleted in mouse models, a significant number of animals developed colitis [35] . However, after rederiving TLR5-null mice with standard microbiota, the animals developed mild intestinal inflammation and by 20 weeks of age developed obesity, preferential increases in visceral fat, dyslipidemia, and insulin resistance [36 ] . The TLR5-null mice also had altered microbiota, which when transplanted to germ-free wild-type mice induced obesity. Although this study does not definitively link intestinal inflammation to obesity and insulin resistance, it emphasizes the key points that host receptors for bacterial ligands can impact gut microbial communities and can be protective against both intestinal inflammation and obesity.
Mechanisms by which gut inflammation itself may affect obesity or insulin resistance
A key unanswered question is whether diet-induced intestinal inflammation itself, in absence of systemic inflammation, is sufficient to initiate or promote insulin resistance or obesity. Evidence in the literature points to several potential mechanisms. Vagal afferant neurons (VANs) within the intestinal wall mediate satiety by a cholecystokinin/CCK 1 R pathway acting on the central nervous system feeding centers [37 ] . HFD impairs sensitivity of this pathway and promotes hyperphagia. Intestinal inflammation itself could act locally on VAN to alter their sensitivity, although this remains to be formally tested. HFD and bacteria and associated inflammation may also impact enteroendocrine cells, which impact feeding, metabolic pathways linked to obesity, or insulin synthesis and secretion. Recent studies demonstrate that a western HFD increases serotonin availability by increasing serotonin-synthesizing enterochromaffin cells, serotonin-synthesis genes, and by decreasing transporters for serotonin reuptake [38] . Although this has not yet been linked to diet-associated intestinal inflammation, it is known that inflammation in other settings increases in enterochromaffin cells. Serotonin reduces gut motility [38] , and therefore HFD-induced increases in serotonin and reduced motility may favor more efficient processing of ingested nutrients or fat, or could mediate dietinduced alterations in specific microbiota. Glucagon-like peptides (GLPs) are synthesized in intestinal L cells and are derived from a common intestinal proglucagon precursor. GLP-1 promotes insulin synthesis and secretion [39, 40] . GLP-2 promotes intestinal growth, has antiinflammatory effects, and improves gut permeability [41] [42] [43] . Both GLP-1 and GLP-2 are implicated as mediators of the beneficial effects of prebiotics to protect against weight gain, insulin resistance, and diet-induced increases in intestinal permeability [39, 40, 43, 44] . Further studies are required to define whether interactions between diet and endogenous bacteria, or their proinflammatory effects on intestinal epithelium, affect L cells, GLP-1, or GLP-2 secretion or action.
Conclusion
Mounting evidence links HFD and diet-induced obesity to low-grade intestinal inflammation. As indicated in the model in Fig. 2 , we propose that diet interacts with intestinal microbiota to promote early inflammatory changes in the intestine, particularly the small intestine, which favor obesity and insulin resistance. Much remains to be done to define precisely how mild intestinal inflammation favors obesity and insulin resistance, but mechanisms likely include altered epithelial permeability, translocation of bacterial products, upregulation of proinflammatory cytokines, hormones produced from gut endocrine cells, and modulation of neural signaling between gut and brain that impacts appetite or satiety. Future studies should dissect the temporal course and specific roles of intestinal inflammation and associated functional effects in mediating obesity and insulin resistance compared with those related to systemic and adipose inflammation. 
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